Analysis of Proton Pump Inhibitors in Bulk and In Different Dosage Forms -A Review
Proton-pump inhibitors (PPIs) produce a pronounced and long-lasting effect for the reduction of gastric acid production. They form majority of benzimidazole derivatives, but promising new research indicates the imidazopyridine derivatives may be a more effective means of treatment. Proton pump inhibitors are mainly used to treat symptoms of gastroesophageal reflux disease and gastritis. Often, they are used only after therapy with histamine-2 (H2) receptor antagonists, commonly called H2 blockers, has been unsuccessful for symptoms of reflux. Proton pump inhibitors also are used to treat peptic ulcers (duodenal and gastric) and drug-induced ulcers, such as those associated with nonsteroidal anti-inflammatory drugs; the bacterium that causes ulcers, Helicobacter pylori, is eradicated by treatment with a proton pump inhibitor and antibiotics. Proton pump inhibitors also are used to promote healing of erosive esophagitis. Esophagitis can lead to scarring and narrowing of the esophagus (stricture) or to Barrett esophagus, which is a risk factor for esophageal cancer. Dyspepsia, Peptic ulcer, Gastroesophageal reflux disease (GERD), Laryngopharyngeal reflux. Clinically used PPIs are Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Esomeprazole.etc Due to rapid degradation of these drugs in acidic and aqueous media, it is challenging to develop analytical method where in stability of drug is least hampered. This review entails different methods developed for determination of PPIs like UV-Spectroscopy, liquid Chromatography and LC-MS.